Keyword: Ian Read

Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.

Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.

Investors who've been waiting to see whether serial acquirer Pfizer would strike a megadeal for Bristol-Myers Squibb can cool it, one analyst says.

Pfizer’s board of directors is providing rich incentives to keep CEO Ian Read on board as the company navigates a host of challenges.

Despite competitors' efforts to pick up market share, an analyst figures J&J's Remicade will dominate the market again in 2018.

Pfizer's Prevnar turned in consensus-beating sales of $1.53 billion in Q4, thanks to government purchases internationally and in the U.S.

The way Pfizer CEO Ian Read sees it, congratulations are well deserved for his company's tax reform lobbying efforts.

Pfizer’s finally getting what it always wanted in U.S. tax reform. And now, all eyes are on what it will do next.

With an impending drop in the corporate tax rate, Pfizer is providing a preview of what Big Pharma's priorities are likely to be.

A new report found that spending on pharmaceuticals grew at a much slower rate last year than in recent history.